ciprofloxacin has been researched along with Middle Ear Effusion in 25 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the efficacy, safety, and microbiology of a thermosensitive otic suspension of ciprofloxacin (OTO-201) in children with bilateral middle ear effusion undergoing tympanostomy tube placement." | 9.22 | Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes. ( Bear, M; LeBel, C; Moss, JR; Park, AH; White, DR, 2016) |
| " Safety was assessed for serious adverse events and treatment-emergent adverse events using audiometry, otoscopy, and tympanometry." | 6.82 | Safety and Efficacy of Intratympanic Ciprofloxacin Otic Suspension in Children With Middle Ear Effusion Undergoing Tympanostomy Tube Placement: Two Randomized Clinical Trials. ( Bear, M; Don, D; Koempel, J; LeBel, C; Mair, EA; Park, AH, 2016) |
| "To investigate the efficacy, safety, and microbiology of a thermosensitive otic suspension of ciprofloxacin (OTO-201) in children with bilateral middle ear effusion undergoing tympanostomy tube placement." | 5.22 | Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes. ( Bear, M; LeBel, C; Moss, JR; Park, AH; White, DR, 2016) |
| "This study demonstrated that treatment with a combination of topical ciprofloxacin and corticosteroid decreased the middle ear effusion when compared with the control group and that ciprofloxacin/dexamethasone suspension reduced the severity of LPS-induced experimental otitis media more than ciprofloxacin/hydrocortisone did." | 3.77 | Effect of ciprofloxacin/dexamethasone versus ciprofloxacin/hydrocortisone on lipopolysaccharide-induced experimental otitis media. ( Chung, YS; Dattaray, P; Jahng, P; Jung, T; Kim, YH; Martin, D; Nyc, MA; Pudrith, C; Wall, GM, 2011) |
| " Safety was assessed for serious adverse events and treatment-emergent adverse events using audiometry, otoscopy, and tympanometry." | 2.82 | Safety and Efficacy of Intratympanic Ciprofloxacin Otic Suspension in Children With Middle Ear Effusion Undergoing Tympanostomy Tube Placement: Two Randomized Clinical Trials. ( Bear, M; Don, D; Koempel, J; LeBel, C; Mair, EA; Park, AH, 2016) |
| "Ciprofloxacin/dexamethasone treatment is also superior to improvement in clinical response by visit, absence of otorrhea by visit, and reduction of otorrhea volume by visit." | 2.71 | Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of children with acute otitis media with otorrhea through tympanostomy tubes. ( Anon, JB; Conroy, PJ; Dupre, SJ; Hogg, G; Kreisler, LS; Lanier, B; McLean, C; Potts, S; Reese, B; Roland, PS; Stroman, DW; Wall, GM, 2004) |
| "Twelve patients had no recurrence at 3 to 15 months after the study." | 1.30 | Efficacy of ototopical ciprofloxacin in pediatric patients with otorrhea. ( Hart, MC; Nahata, MC; Wintermeyer, SM, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gohil, RD | 1 |
| Syed, MI | 1 |
| Dombrowski, T | 1 |
| Gabarain, G | 1 |
| Baird, R | 1 |
| Morisada, M | 1 |
| Anne, S | 1 |
| Hopkins, B | 1 |
| Vazquez, A | 1 |
| Blake, DM | 1 |
| Jyung, RW | 1 |
| Faramarzi, M | 1 |
| Roosta, S | 1 |
| Shishegar, M | 1 |
| Abbasi, R | 1 |
| Atighechi, S | 1 |
| Mair, EA | 2 |
| Moss, JR | 2 |
| Dohar, JE | 4 |
| Antonelli, PJ | 1 |
| Bear, M | 3 |
| LeBel, C | 3 |
| Park, AH | 2 |
| Don, D | 1 |
| Koempel, J | 1 |
| White, DR | 1 |
| Yazici, A | 1 |
| Naiboglu, B | 1 |
| Oysu, C | 1 |
| Toros, SZ | 1 |
| Noseri, H | 1 |
| Karaca, CT | 1 |
| Egeli, E | 1 |
| Dattaray, P | 1 |
| Pudrith, C | 1 |
| Nyc, MA | 1 |
| Martin, D | 1 |
| Kim, YH | 1 |
| Jahng, P | 1 |
| Chung, YS | 1 |
| Wall, GM | 3 |
| Jung, T | 1 |
| Silva, RC | 1 |
| Hebda, PA | 2 |
| Lee, DH | 1 |
| Roland, PS | 2 |
| Kreisler, LS | 1 |
| Reese, B | 1 |
| Anon, JB | 1 |
| Lanier, B | 1 |
| Conroy, PJ | 2 |
| Dupre, SJ | 2 |
| Potts, S | 1 |
| Hogg, G | 1 |
| Stroman, DW | 1 |
| McLean, C | 1 |
| Nawasreh, O | 1 |
| Al-Wedyan, IA | 1 |
| Lanier, BJ | 1 |
| Hekkenburg, R | 1 |
| Lane, EM | 1 |
| Potts, SL | 1 |
| Kumar, VV | 1 |
| Gaughan, J | 1 |
| Isaacson, G | 1 |
| Szeremeta, W | 1 |
| Jang, CH | 1 |
| Cho, YB | 1 |
| Choi, CH | 1 |
| Yuksel, S | 1 |
| Jha, AK | 1 |
| Singh, JB | 1 |
| Dutta, D | 1 |
| Wintermeyer, SM | 1 |
| Hart, MC | 1 |
| Nahata, MC | 1 |
| Ozagar, A | 1 |
| Koç, A | 1 |
| Ciprut, A | 1 |
| Tutkun, A | 1 |
| Akdaş, F | 1 |
| Sehitoğlu, MA | 1 |
| Fontanel, JP | 1 |
| Hartnick, CJ | 1 |
| Shott, S | 1 |
| Willging, JP | 1 |
| Myer, CM | 1 |
| Morpeth, JF | 1 |
| Bent, JP | 1 |
| Watson, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, P3 Study of OTO-201 Given as a Single IT Injection For Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement[NCT01949142] | Phase 3 | 266 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, P3 Study of OTO-201 Given as a Single IT Injection For Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement[NCT01949155] | Phase 3 | 266 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects whose samples tested positive for bacteria in either or both ears. (NCT01949142)
Timeframe: Day 15 - 2 weeks after dosing
| Intervention | percentage of Microbiological response (Number) |
|---|---|
| OTO-201 | 81 |
| Sham | 41 |
"Cumulative proportion of treatment failures:~The efficacy endpoint for both trials was the cumulative proportion of study treatment failures through Day 15, defined as the occurrence of any of the following events: otorrhea as determined by a blinded assessor on or after 3 days post-surgery, otic or systemic antibacterial drug use for any reason any time post-surgery, as well as patients who missed visits or were lost-to-follow-up." (NCT01949142)
Timeframe: Day 15 - 2 weeks after dosing
| Intervention | percentage of treatment failures (Number) |
|---|---|
| OTO-201 | 24.6 |
| Sham | 44.8 |
Safety variables included the frequency of adverse events (AEs) and results from otoscopic examinations, tympanometry, audiometry, vital sign measurements, and physical examinations. (NCT01949142)
Timeframe: Up to one month
| Intervention | percentage of ears (Number) | |||||
|---|---|---|---|---|---|---|
| Otoscopic abnormal exams @ day 29-left ear | Otoscopic abnormal exams @ day 29-right ear | Audiometry Patent tubes @ day 29-left ear | Audiometry Patent tubes @ day 29-right ear | Tympanometry Category of B (large) day 29-left ear | Tympanometry Category of B (large)day 29-right ear | |
| OTO-201 | 1.1 | 0.6 | 98.3 | 96.0 | 89.2 | 91.0 |
| Sham | 2.4 | 0.0 | 94.1 | 96.5 | 84.1 | 88.9 |
Subjects whose samples tested positive for bacteria in either or both ears at baseline with documented eradication or presumed eradication post-baseline. (NCT01949155)
Timeframe: Day 15 - 2 weeks after dosing
| Intervention | percentage of Microbiological response (Number) |
|---|---|
| OTO-201 | 83 |
| Sham | 48 |
"Cumulative proportion of treatment failures:~The efficacy endpoint for both trials was the cumulative proportion of study treatment failures through Day 15, defined as the occurrence of any of the following events: otorrhea as determined by a blinded assessor on or after 3 days post-surgery, otic or systemic antibacterial drug use for any reason any time post-surgery, as well as patients who missed visits or were lost-to-follow-up." (NCT01949155)
Timeframe: Day 15 - 2 weeks after dosing
| Intervention | percentage of treatment failures (Number) |
|---|---|
| OTO-201 | 21.3 |
| Sham | 45.5 |
Safety variables included the frequency of adverse events (AEs) and results from otoscopic examinations, tympanometry, audiometry measurements. (NCT01949155)
Timeframe: Up to one month
| Intervention | percentage of ears (Number) | |||||
|---|---|---|---|---|---|---|
| Otoscopic abnormal exams @ day 29-left ear | Otoscopic abnormal exams @ day 29-right ear | Audiometry Patent tubes @ day 29 left ear | Audiometry Patent tubes @ day 29 right ear | Tympanometry Category of B (large) day 29 left ear | Tympanometry Category of B (large)day 29 right ear | |
| OTO-201 | 1.7 | 1.7 | 96.0 | 96.0 | 87.9 | 88.2 |
| Sham | 2.4 | 3.5 | 100 | 96.5 | 87.1 | 84.5 |
11 trials available for ciprofloxacin and Middle Ear Effusion
| Article | Year |
|---|---|
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Drug Therapy, Combination; Female; Fl | 2017 |
Early Otorrhea Rates: A Randomized Trial of Ciprofloxacin versus Saline Drops after Tympanostomy Tubes.
Topics: Administration, Topical; Anti-Bacterial Agents; Child, Preschool; Ciprofloxacin; Female; Humans; Inc | 2019 |
The rationale for preventive treatments for early post-tympanostomy tube otorrhea in persistent otitis media with effusion.
Topics: Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Female; Humans; Incidenc | 2016 |
Randomized Clinical Trial of a Sustained-Exposure Ciprofloxacin for Intratympanic Injection During Tympanostomy Tube Surgery.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Delayed-Action Preparations; Dose-Res | 2016 |
Safety and Efficacy of Intratympanic Ciprofloxacin Otic Suspension in Children With Middle Ear Effusion Undergoing Tympanostomy Tube Placement: Two Randomized Clinical Trials.
Topics: Adolescent; Anti-Bacterial Agents; Audiometry, Pure-Tone; Bone Conduction; Child; Child, Preschool; | 2016 |
Safety and Efficacy of Intratympanic Ciprofloxacin Otic Suspension in Children With Middle Ear Effusion Undergoing Tympanostomy Tube Placement: Two Randomized Clinical Trials.
Topics: Adolescent; Anti-Bacterial Agents; Audiometry, Pure-Tone; Bone Conduction; Child; Child, Preschool; | 2016 |
Safety and Efficacy of Intratympanic Ciprofloxacin Otic Suspension in Children With Middle Ear Effusion Undergoing Tympanostomy Tube Placement: Two Randomized Clinical Trials.
Topics: Adolescent; Anti-Bacterial Agents; Audiometry, Pure-Tone; Bone Conduction; Child; Child, Preschool; | 2016 |
Safety and Efficacy of Intratympanic Ciprofloxacin Otic Suspension in Children With Middle Ear Effusion Undergoing Tympanostomy Tube Placement: Two Randomized Clinical Trials.
Topics: Adolescent; Anti-Bacterial Agents; Audiometry, Pure-Tone; Bone Conduction; Child; Child, Preschool; | 2016 |
Phase 3 Trials of Thermosensitive Ciprofloxacin Gel for Middle Ear Effusion in Children with Tubes.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Double-Blind Method; Fema | 2016 |
Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of children with acute otitis media with otorrhea through tympanostomy tubes.
Topics: Acute Disease; Administration, Topical; Anti-Infective Agents; Anti-Inflammatory Agents; Child; Chil | 2004 |
Prophylactic ciprofloxacin drops after tympanostomy tube insertion.
Topics: Administration, Topical; Adolescent; Antibiotic Prophylaxis; Child; Child, Preschool; Ciprofloxacin; | 2004 |
Topical ciprofloxacin/dexamethasone otic suspension is superior to ofloxacin otic solution in the treatment of granulation tissue in children with acute otitis media with otorrhea through tympanostomy tubes.
Topics: Administration, Topical; Adolescent; Anti-Infective Agents; Anti-Inflammatory Agents; Cerebrospinal | 2004 |
Effects of topical otic preparations on hearing in chronic otitis media.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Audi | 1997 |
A comparison of cortisporin and ciprofloxacin otic drops as prophylaxis against post-tympanostomy otorrhea.
Topics: Administration, Topical; Chi-Square Distribution; Child; Child, Preschool; Ciprofloxacin; Confidence | 2001 |
14 other studies available for ciprofloxacin and Middle Ear Effusion
| Article | Year |
|---|---|
The SIGN 104 guideline (2014) for topical antibiotic prophylaxis during grommet insertion: Misguided?
Topics: Administration, Topical; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Clinical Prot | 2018 |
Eosinophilic otitis media.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Ciprofloxacin; Dexamethasone; Eosinophilia; Femal | 2014 |
Ciprofloxacin (Otiprio) for tympanostomy tube insertion.
Topics: Adolescent; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Cerebrospinal Fluid | 2016 |
Effect of ototopical ciprofloxacin-dexamethasone on myringotomy in a rat model.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Ciprofloxacin; De | 2009 |
Effect of ciprofloxacin/dexamethasone versus ciprofloxacin/hydrocortisone on lipopolysaccharide-induced experimental otitis media.
Topics: Administration, Topical; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chinchilla; Cipro | 2011 |
Novel rat model of tympanostomy tube otorrhea.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Cytokines; Dexamethasone; Disease Models, Animal; Eus | 2012 |
Reply to: Novel rat model of tympanostomy tube otorrhea.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dexamethasone; Disease Models, Animal; Male; Middle E | 2012 |
Oxymetazoline is equivalent to ciprofloxacin in preventing postoperative otorrhea or tympanostomy tube obstruction.
Topics: Administration, Topical; Adolescent; Adrenergic alpha-Agonists; Anti-Infective Agents; Antibiotic Pr | 2005 |
Structural features of tympanostomy tube biofilm formation in ciprofloxacin-resistant Pseudomonas otorrhea.
Topics: Anti-Infective Agents; Biofilms; Child; Ciprofloxacin; Drug Resistance, Bacterial; Female; Humans; I | 2007 |
Effects of ciprofloxacin-dexamethasone on myringotomy wound healing.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Dexamethasone; Disease Models, Animal; Drug Combinati | 2007 |
Microorganisms present in discharging otitis media in a group of patients in Kathmandu.
Topics: Acute Disease; Adolescent; Adult; Amikacin; Ciprofloxacin; Female; Gentamicins; Humans; Klebsiella p | 2007 |
Efficacy of ototopical ciprofloxacin in pediatric patients with otorrhea.
Topics: Administration, Topical; Adolescent; Anti-Infective Agents; Child; Child, Preschool; Ciprofloxacin; | 1997 |
[Role of ciprofloxacin in the treatment of chronic otitis media].
Topics: Administration, Oral; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; A | 1998 |
Methicillin-resistant Staphylococcus aureus otorrhea after tympanostomy tube placement: an emerging concern.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infect | 2000 |